Renal Denervation Devices Market, By Procedure Type (Percutaneous Renal Denervation, Radiofrequency Renal Denervation, Ultrasound Renal Denervation, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
In November 17, 2023, Medtronic, a medical device company, received approval from the U.S. Food and Drug Administration (FDA) Medtronic Symplicity Spyral renal denervation system for use in the U.S.
In November 10, 2023, Recor Medical, Inc., a medical device company, announced the first commercial use of Recor’s Paradise Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first U.S.FDA approved renal denervation therapy in the U.S.